Episode Details

We were delighted to be joined by Johanna Kaufmann, Chief Scientific Officer at Deck Bio.

Johanna has spent her career at the intersection of oncology, immunology and drug development, working across both biotech and big pharma. She started her career in cancer virology before moving through roles at Genocea, TESARO and GSK, and later joined Codagenix, where she led its oncology and immunology efforts.

Today, as CSO at Deck Bio, she’s helping to advance a new approach to targeting solid tumours through multi-peptide-MHC targeted T-cell engagers.

In this we discuss Johanna’s journey through the field, the lessons she’s learned moving between different parts of the industry, how her thinking around drug development has evolved, and what it takes to build and advance innovative science in biotech.